A year ago this month, GT looked at Genaissance Pharmaceuticals and its direct competitor, Variagenics. At the time, Genaissance posited that its gamble on finding haplotypes would pay off in the sale of pharmacogenomic information. Variagenics, meanwhile, pursued its proprietary genotyping technology as the path to riches.
Where are they now?
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.